Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0PE2L
|
|||
| Former ID |
DNCL001576
|
|||
| Drug Name |
GSK2402968
|
|||
| Indication | Duchenne dystrophy [ICD-11: 8C70; ICD-10: G71.0] | Phase 3 | [1] | |
| Company |
GlaxoSmithKline; Prosensa
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dystrophin messenger RNA (DMD mRNA) | Target Info | Modulator | [2], [3] |
| KEGG Pathway | Hypertrophic cardiomyopathy (HCM) | |||
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | ||||
| Dilated cardiomyopathy | ||||
| Viral myocarditis | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| IL5 Signaling Pathway | ||||
| Reactome | Non-integrin membrane-ECM interactions | |||
| Striated Muscle Contraction | ||||
| WikiPathways | Striated Muscle Contraction | |||
| Ectoderm Differentiation | ||||
| Extracellular matrix organization | ||||
| Arrhythmogenic Right Ventricular Cardiomyopathy | ||||
| Muscle contraction | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01480245) Open Label Study of GSK2402968 in Subjects With Duchenne Muscular Dystrophy. U.S. National Institutes of Health. | |||
| REF 2 | Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol. 2014 Oct;13(10):987-96. | |||
| REF 3 | ClinicalTrials.gov (NCT01254019) A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.